Abstract
BACKGROUND--Tuberculous pleurisy can result in pleural fibrosis, calcification and thickening. To prevent these complications, corticosteroids are frequently used in addition to antituberculous drugs; however, new therapeutic regimens can control the disease and minimise the sequelae, and there is no convincing evidence of the benefit of the use of corticosteroids as adjuvant therapy. METHODS--Patients received isoniazid 5 mg/kg and rifampicin 10 mg/kg daily for six months. Additionally, they were randomly assigned to a double blind treatment with either prednisone (1 mg/kg/day for 15 days and then tapering off) or placebo during the first month of treatment. Different clinical, radiological, and functional parameters were evaluated to assess the effect of corticosteroids. RESULTS--Fifty seven patients received prednisone and 60 placebo. At the end of the treatment the clinical outcome, the rate of reabsorption of the pleural fluid, the pleural sequelae, as well as lung capacity were similar in both groups. CONCLUSIONS--Corticosteroids do not influence the clinical outcome or the development of long term pleural sequelae in tuberculous pleurisy.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cañete C., Galarza I., Granados A., Farrero E., Estopà R., Manresa F. Tuberculous pleural effusion: experience with six months of treatment with isoniazid and rifampicin. Thorax. 1994 Nov;49(11):1160–1161. doi: 10.1136/thx.49.11.1160. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dutt A. K., Moers D., Stead W. W. Smear-negative, culture-positive pulmonary tuberculosis. Six-month chemotherapy with isoniazid and rifampin. Am Rev Respir Dis. 1990 May;141(5 Pt 1):1232–1235. doi: 10.1164/ajrccm/141.5_Pt_1.1232. [DOI] [PubMed] [Google Scholar]
- Dutt A. K., Moers D., Stead W. W. Tuberculous pleural effusion: 6-month therapy with isoniazid and rifampin. Am Rev Respir Dis. 1992 Jun;145(6):1429–1432. doi: 10.1164/ajrccm/145.6.1429. [DOI] [PubMed] [Google Scholar]
- Grewal K. S., Dixit R. P., Sil D. R. A comparative study of therapeutic regimens with and without corticosteroids in the treatment of tuberculous pleural effusion. J Indian Med Assoc. 1969 Jun 1;52(11):514–516. [PubMed] [Google Scholar]
- Lee C. H., Wang W. J., Lan R. S., Tsai Y. H., Chiang Y. C. Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study. Chest. 1988 Dec;94(6):1256–1259. doi: 10.1378/chest.94.6.1256. [DOI] [PubMed] [Google Scholar]
- MENON N. K. STEROID THERAPY IN TUBERCULOUS PLEURAL EFFUSION. Tubercle. 1964 Mar;45:17–20. doi: 10.1016/s0041-3879(64)80082-9. [DOI] [PubMed] [Google Scholar]
- McAllister W. A., Thompson P. J., Al-Habet S. M., Rogers H. J. Rifampicin reduces effectiveness and bioavailability of prednisolone. Br Med J (Clin Res Ed) 1983 Mar 19;286(6369):923–925. doi: 10.1136/bmj.286.6369.923. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Seibert A. F., Haynes J., Jr, Middleton R., Bass J. B., Jr Tuberculous pleural effusion. Twenty-year experience. Chest. 1991 Apr;99(4):883–886. doi: 10.1378/chest.99.4.883. [DOI] [PubMed] [Google Scholar]
- Senderovitz T., Viskum K. Corticosteroids and tuberculosis. Respir Med. 1994 Sep;88(8):561–565. doi: 10.1016/s0954-6111(05)80002-2. [DOI] [PubMed] [Google Scholar]